1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: RPCI-I-72806, I 72806, NCT00536601
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: FHCRC-1803.00, 5606, NCT00068718
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-06077, NCT00423852
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 20406, NCT00674427
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 4T-03-1, NCT00183820
|
|
8.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UMN-2005NT018, UMN-0506M70866, UMN-MT2005-06, NOVARTIS-CZOL446EUS29, NCT00321932
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0609-11, IUCRO-0166, AVF4003s, NCT00393861
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 21 at original diagnosis
Sponsor: NCI
Protocol IDs: COG-AGCT0521, AGCT0521, NCT00467051
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: UMN-2007LS072, UMN-2007LS072, UMN-MT2007-07, NCT00617929
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: FHCRC-07156, 07156, CHNMC-07156, NCT00627601
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Other
Protocol IDs: umcc 2007.137, HUM00017515, NCT00763490
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-09034, 09-034, 8258, NCT00957905
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0685, NCT00912912
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2008-0378, NCT00936936
|
|
18.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: BCM-H-6676, H 6676, BCM-ETNA, NCT00608309
|
|
19.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 00005124, NCT00586690
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 00005123, NCT00586703
|
|
21.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: Under 55
Sponsor: Other
Protocol IDs: 561-2003, NCT00231309
|
|
22.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: not specified
Sponsor: Other
Protocol IDs: 234, NCT00212407
|
|
23.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 06U.20, NCT00429143
|
|
24.
|
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 months to 40
Sponsor: NCI
Protocol IDs: CHNMC-03112, 03112, NCT00638898
|
|
25.
|
Phase: No phase specified
Type: Treatment
Status: Active
Age: 3 to 60
Sponsor: Other
Protocol IDs: Intraosseous Infusion, NCT00967525
|
